Advertisement
Research Article| Volume 45, ISSUE 2, P268-274, January 2009

Lessons learned from independent central review

Published:December 22, 2008DOI:https://doi.org/10.1016/j.ejca.2008.10.031
Lessons learned from independent central review
Previous ArticleEvaluation of lymph nodes with RECIST 1.1
Next ArticleOptimising the design of phase II oncology trials: The importance of randomisation

      Abstract

      Independent central review (ICR) is advocated by regulatory authorities as a means of independent verification of clinical trial end-points dependent on medical imaging, when the data from the trials may be submitted for licensing applications [Food and Drug Administration. United States food and drug administration guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: US Department of Health and Human Services; 2007; Committee for Medicinal Products for Human Use. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) guideline on the evaluation of anticancer medicinal products in man. London, UK: European Medicines Agency; 2006; United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 21-492 (oxaliplatin). Rockville, MD: US Department of Health and Human Services; 2002; United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 21-923 (sorafenib tosylate). Rockville, MD: US Department of Health and Human Services; 2005; United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 22-065 (ixabepilone). Rockville, MD: US Department of Health and Human Services; 2007; United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 22-059 (lapatinib ditosylate). Rockville, MD: US Department of Health and Human Services; 2007; United States Food and Drug Administration Center for Biologics Evaluation and Research. Approval package for BLA numbers 97-0260 and BLA Number 97-0244 (rituximab). Rockville, MD: US Department of Health and Human Services; 1997; United States Food and Drug Administration. FDA clinical review of BLA 98-0369 (Herceptin® trastuzumab (rhuMAb HER2)). FDA Center for Biologics Evaluation and Research; 1998; United States Food and Drug Administration. FDA Briefing Document Oncology Drugs Advisory Committee meeting NDA 21801 (satraplatin). Rockville, MD: US Department of Health and Human Services; 2007; Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. JCO 2007(November):5210–7]. In addition, clinical trial sponsors have used ICR in Phase I–II studies to assist in critical pathway decisions including in-licensing of compounds [Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. JCO 2007(November):5180–6; Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. JCO 2007(August):3407–14; Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. JCO 2007(June):2171–7; Ghassan KA, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. JCO 2006(September):4293–300; Boué F, Gabarre J, GaBarre J, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. JCO 2006(September):4123–8; Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. JCO 2006(July):3354–60; Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. JCO 2006(June):2502–12; Jaffer AA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. JCO 2006(February):663–7; Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803. JCO 2004(November):4319–28]. This article will focus on the definition and purpose of ICR and the issues and lessons learned in the ICR setting primarily in Phase II and III oncology studies. This will include a discussion on discordance between local and central interpretations, consequences of ICR, reader discordance during the ICR, operational considerations and the need for specific imaging requirements as part of the study protocol.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Food and Drug Administration. United States food and drug administration guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: US Department of Health and Human Services; 2007.

        View in Article

      2. Committee for Medicinal Products for Human Use. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) guideline on the evaluation of anticancer medicinal products in man. London, UK: European Medicines Agency; 2006.

        View in Article

      3. United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 21-492 (oxaliplatin). Rockville, MD: US Department of Health and Human Services; 2002.

        View in Article

      4. United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 21-923 (sorafenib tosylate). Rockville, MD: US Department of Health and Human Services; 2005.

        View in Article

      5. United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 22-065 (ixabepilone). Rockville, MD: US Department of Health and Human Services; 2007.

        View in Article

      6. United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 22-059 (lapatinib ditosylate). Rockville, MD: US Department of Health and Human Services; 2007.

        View in Article

      7. United States Food and Drug Administration Center for Biologics Evaluation and Research. Approval package for BLA numbers 97-0260 and BLA Number 97-0244 (rituximab). Rockville, MD: US Department of Health and Human Services; 1997.

        View in Article

      8. United States Food and Drug Administration. FDA clinical review of BLA 98-0369 (Herceptin® trastuzumab (rhuMAb HER2)). FDA Center for Biologics Evaluation and Research; 1998.

        View in Article

      9. United States Food and Drug Administration. FDA Briefing Document Oncology Drugs Advisory Committee meeting NDA 21801 (satraplatin). Rockville, MD: US Department of Health and Human Services; 2007.

        View in Article
        • Thomas E.S.
        • Gomez H.L.
        • Li R.K.
        • et al.
        Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
        JCO. 2007; : 5210-5217
        View in Article
        • Cannistra S.A.
        • Matulonis U.A.
        • Penson R.T.
        • et al.
        Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
        JCO. 2007; : 5180-5186
        View in Article
        • Perez E.A.
        • Lerzo G.
        • Pivot X.
        • et al.
        Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
        JCO. 2007; : 3407-3414
        View in Article
        • Vermorken J.B.
        • Trigo J.
        • Hitt R.
        • et al.
        Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
        JCO. 2007; : 2171-2177
        View in Article
        • Ghassan K.A.
        • Schwartz L.
        • Ricci S.
        • et al.
        Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
        JCO. 2006; : 4293-4300
        View in Article
        • Boué F.
        • Gabarre J.
        • GaBarre J.
        • et al.
        Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma.
        JCO. 2006; : 4123-4128
        View in Article
        • Chen H.X.
        • Mooney M.
        • Boron M.
        • et al.
        Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
        JCO. 2006; : 3354-3360
        View in Article
        • Ratain M.J.
        • Eisen T.
        • Stadler W.M.
        • et al.
        Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
        JCO. 2006; : 2502-2512
        View in Article
        • Jaffer A.A.
        • Lee F.C.
        • Singh D.A.
        • et al.
        Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
        JCO. 2006; : 663-667
        View in Article
        • Bouché O.
        • Raoul J.L.
        • Bonnetain F.
        • et al.
        Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803.
        JCO. 2004; : 4319-4328
        View in Article
        • Miller K.D.
        • Chap L.I.
        • Holmes F.A.
        • et al.
        Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
        JCO. 2005; : 792-799
        View in Article

      21. Code of Federal Regulations. Title 21, part 54. Financial disclosure by clinical investigators.

        View in Article
        • Gwyther S.
        • Bolis G.
        • Gore M.
        • et al.
        Experience with independent radiological review during a topotecan trial in ovarian cancer.
        Ann Oncol. 1997; 8: 463-468
        View in Article
        • Rothenberg M.L.
        • Oza A.M.
        • Bigelow R.H.
        • et al.
        Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
        JCO. 2003; 21: 2059-2069
        View in Article
        • Hopper K.D.
        • Kasales C.J.
        • Van Slyke M.A.
        • Schwartz T.A.
        • TenHave T.R.
        • Jozefiak J.A.
        Analysis of interobserver and intraobserver variability in CT tumor measurements.
        Am J Roentgenol. 1996; 167: 851-854
        View in Article

      25. FDA guidance for industry developing medical imaging drug and biologic products part three: design, analysis and interpretation of clinical studies; June 2004.

        View in Article

      26. United States Food and Drug Administration Oncologic Drugs Advisory Committee briefing document for NDA 21-649 (oblimersen sodium).

        View in Article

      27. United States Food and Drug Administration Oncologic Drugs Advisory Committee briefing document. BLA STN 125085/91.018 (bevacizumab); 5th December 2007.

        View in Article

      28. US Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number 20-509/S029 (gemcitabine hydrochloride). Rockville, MD: US Department of Health and Human Services.

        View in Article
        • Dodd L.E.
        • Korn E.L.
        • Freidlin B.
        • et al.
        Blinded independent central review of progression free survival in phase III clinical trials: important design element or unnecessary expense?.
        JCO. 2008; 26: 3791-3796
        View in Article

      Article info

      Publication history

      Published online: December 22, 2008
      Accepted: October 29, 2008
      Received: October 17, 2008

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2008.10.031

      Copyright

      © 2008 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX